Evodiamine sensitizes BGC-823 gastric cancer cells to radiotherapy in vitro and in vivo

doi:10.3892/mmr.2016.5237

CORC > 兰州大学 > 兰州大学 > 口腔医学院 > 期刊论文

	Evodiamine sensitizes BGC-823 gastric cancer cells to radiotherapy in vitro and in vivo
	Hu, CQ; Gao, XX; Han, YY; Guo, Q; Zhang, KL; Liu, MM; Wang, YG; Wang, J; Wang, J (reprint author), Lanzhou Univ, Sch Stomatol, Dept Oral Med, 222 Tianshui South Rd, Lanzhou 730000, Gansu, Peoples R China.; Wang, YG (reprint author), Univ Michigan, Sch Med, Dept Urol, 1301 Catherine St, Ann Arbor, MI 48109 USA.
刊名	MOLECULAR MEDICINE REPORTS
	2016-07
卷号	14 期号:1 页码:413-419
关键词	evodiamin BGC-823 radiotherapy Bcl-2 AKT Her-2
ISSN号	1791-2997
DOI	10.3892/mmr.2016.5237
文献子类	Article
英文摘要	The present study aimed to investigate the ability of evodiamin (EVO) to sensitize BGC-823 gastric cancer cells to radiotherapy and to elucidate the underlying mechanisms. First, the sensitizing effects of EVO to radiation were demonstrated in vitro using an MTT and a clonogenic assay. Flow cytometric analysis further revealed that the inhibition of cell cycle progression of BGC-823 cells by radiation was enhanced by EVO in vitro. Furthermore, BGC-823 cell-derived xenograft models were established and animals were divided into the following four treatment groups: Control group, evodiamin group, radiotherapy group and combined therapy group. The volume and weight of the xenograft tumors were measured, from which the tumor the tumor growth curve was drawn and the inhibition rate was calculated, respectively. The results revealed that combined therapy inhibited tumor growth to a greater extent than mono treatments. The tumor inhibition rate and the level of apoptosis in the combination group (48.8%) were significantly higher than those in the other groups (P<0.05). Immunohistochemistry was used to reveal that the expression of Bcl-2, phosphorylated Akt and Her-2 was significantly decreased, while Bax was increased in the xenograft tumors subjected to radiation, which was significantly enhanced by EVO. In conclusion, EVO was demonstrated to sensitize BGC-823 cells to radiation therapy and markedly inhibited xenograft tumor growth. Furthermore, downregulation of Her-2/AKT/Bcl-2 signaling was shown to be involved in this process. These results suggested that EVO may be a good candidate for combined therapy with radiation in the treatment of human gastric cancer.
学科主题	Oncology ; Research & Experimental Medicine
出版地	ATHENS
资助项目	国家自然科学基金项目 ; 甘肃省自然科学基金计划
项目编号	National Natural Science Foundation of China [81372893] ; Natural Science Foundation of Gansu Province [1208RJZA193]
语种	英语
WOS记录号	WOS:000379551700054
资助机构	NSFC ; GSSTD
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/179502]
专题	口腔医学院_期刊论文
通讯作者	Wang, J (reprint author), Lanzhou Univ, Sch Stomatol, Dept Oral Med, 222 Tianshui South Rd, Lanzhou 730000, Gansu, Peoples R China.; Wang, YG (reprint author), Univ Michigan, Sch Med, Dept Urol, 1301 Catherine St, Ann Arbor, MI 48109 USA.
推荐引用方式 GB/T 7714	Hu, CQ,Gao, XX,Han, YY,et al. Evodiamine sensitizes BGC-823 gastric cancer cells to radiotherapy in vitro and in vivo[J]. MOLECULAR MEDICINE REPORTS,2016,14(1):413-419.
APA	Hu, CQ.,Gao, XX.,Han, YY.,Guo, Q.,Zhang, KL.,...&Wang, YG .(2016).Evodiamine sensitizes BGC-823 gastric cancer cells to radiotherapy in vitro and in vivo.MOLECULAR MEDICINE REPORTS,14(1),413-419.
MLA	Hu, CQ,et al."Evodiamine sensitizes BGC-823 gastric cancer cells to radiotherapy in vitro and in vivo".MOLECULAR MEDICINE REPORTS 14.1(2016):413-419.